Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window

Affiliations

Editorial

Shauna L French et al. Ann Transl Med. 2017 Dec.

. 2017 Dec;5(23):464.

doi: 10.21037/atm.2017.09.10.

¹ Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

On the article "Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window".
Wong PC, Yang J. Wong PC, et al. Ann Transl Med. 2018 Feb;6(3):71. doi: 10.21037/atm.2017.11.31. Ann Transl Med. 2018. PMID: 29611552 Free PMC article. No abstract available.

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang J. Wong PC, et al. Sci Transl Med. 2017 Jan 4;9(371):eaaf5294. doi: 10.1126/scitranslmed.aaf5294. Sci Transl Med. 2017. PMID: 28053157

1. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. 10.1136/bmj.324.7329.71 - DOI - PMC - PubMed
1. French SL, Arthur JF, Tran HA, et al. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Rev 2015;29:179-89. 10.1016/j.blre.2014.10.006 - DOI - PubMed
1. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44. 10.1161/01.CIR.100.4.437 - DOI - PubMed
1. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8. 10.1001/jama.295.13.joc60034 - DOI - PubMed
1. Wong PC, Seiffert D, Bird JE, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017;9(371). pii: eaaf5294. 10.1126/scitranslmed.aaf5294 - DOI - PubMed